Anti-Agitation Drug Submitted For FDA Approval
Alexza Pharmaceuticals announced today that it’s submitted a new drug application for Staccato loxapine (AZ-004). It’s an inhalant designed to be used to address cases of agitation in schizophrenia and bipolar disorder. Much of that agitation is often caused by other active treatments patients may be taking (anti-depressants, anti-seizure drugs, antipsychotics), so it does seem a bit wild that a company has developed a drug to deal with it, but that’s the way it goes in the mental health world.
Loxapine itself is a typical antipsychotic that is so seldom used that I’ve never heard of it before now.
Related posts:
- Anti-Depressants, Antipsychotics Worst Drugs For Falls In Elderly
- Reasons To Be Skeptical Of "Female Viagra" Drug, Big Pharma’s Spanish Fly
- The Boston Globe Examines Seroquel’s Street Drug Status
- FDA Panel Recommends Approval Of Antipsychotics For Kids Aged 10, Older
- Seroquel As Street Drug Flooding Scotland